FDA wants investigation into Avandia conflict: report
NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.
David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.
Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.
- Tweet this
- Share this
- Digg this
- Maker of U.S. highway guardrails stops shipments over safety concerns
- Google's Pichai to oversee major products and services
- São Paulo running out of water as rain-making Amazon vanishes
- UPDATE 1-UK's Labour suffers setback as leader in Scotland quits
- India picks Israel's Spike anti-tank missile over U.S. Javelin - source
New York and New Jersey will automatically quarantine medical workers returning from Ebola-hit West African countries and the U.S. government is considering the same step after a doctor who treated patients in Guinea came back infected, officials said. Full Article | Slideshow